Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment

Khan, Firdos Alam; Albalawi, Reem; Pottoo, Faheem Hyder

doi:10.1002/med.21809

Cited by 48 publications

(33 citation statements)

References 225 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biocompatibility of cobalt oxide nanoparticles can also be improved by forming composite materials with other materials, for example, using silica as the protective shell of cobalt oxide nanoparticles, which significantly in-creases their biocompatibility [44]. In addition, similar to what Khan et al reported [49], the biocompatibility and bioavailability of cobalt oxide nanoparticles can also be improved through the combined use of cobalt oxide nanoparticles and other nano preparations. Additionally, cobalt oxide nanoparticles obtained by different preparation methods have different biocompatibility.…”

Section: Biocompatibility Of Cobalt Oxide Nanoparticlesmentioning

confidence: 73%

Inspirations of Cobalt Oxide Nanoparticle Based Anticancer Therapeutics

et al. 2021

View full text Add to dashboard Cite

Cobalt is essential to the metabolism of all animals due to its key role in cobalamin, also known as vitamin B12, the primary biological reservoir of cobalt as an ultra-trace element. Current cancer treatment strategies, including chemotherapy and radiotherapy, have been seriously restricted by their side effects and low efficiency for a long time, which urges us to develop new technologies for more effective and much safer anticancer therapies. Novel nanotechnologies, based on different kinds of functional nanomaterials, have been proved to act as effective and promising strategies for anticancer treatment. Based on the important biological roles of cobalt, cobalt oxide nanoparticles (NPs) have been widely developed for their attractive biomedical applications, especially their potential for anticancer treatments due to their selective inhibition of cancer cells. Thus, more and more attention has been attracted to the preparation, characterization and anticancer investigation of cobalt oxide nanoparticles in recent years, which is expected to introduce novel anticancer treatment strategies. In this review, we summarize the synthesis methods of cobalt oxide nanoparticles to discuss the advantages and restrictions for their preparation. Moreover, we emphatically discuss the anticancer functions of cobalt oxide nanoparticles as well as their underlying mechanisms to promote the development of cobalt oxide nanoparticles for anticancer treatments, which might finally benefit the current anticancer therapeutics based on functional cobalt oxide nanoparticles.

show abstract

Section: Biocompatibility Of Cobalt Oxide Nanoparticlesmentioning

confidence: 73%

Inspirations of Cobalt Oxide Nanoparticle Based Anticancer Therapeutics

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Colon cancer is a type of adenocarcinoma that can develop into a malignant tumor if treated improperly. Colon cancer is the third leading cause of cancer-related deaths worldwide ( Khan et al., 2022 ). The occurrence of colon cancer is related to numerous factors, including genetic factors, environmental factors, infections with bacteria such as Helicobacter pylori , and changes in gut microbiota.…”

Section: Discussionmentioning

confidence: 99%

“…Colon cancer is one of the three leading causes of cancer-related deaths worldwide ( Khan et al., 2022 ). According to recent statistics, there are approximately 376,300 new cases of colon cancer annually ( Chen et al., 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Changes of gut microbiota in colorectal cancer patients with Pentatrichomonas hominis infection

Gong

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Pentatrichomonas hominis is a parasitic trichomonads protozoa that parasitizes in the colon and cecum of humans and other animals. Our previous studies have demonstrated that infection with P. hominis is associated with the incidence of colon cancer (37.93%). However, the mechanism by which P. hominis infections increase the incidence of colon cancer remains unclear. Previous studies have suggested that certain parasites promote colon cancer by regulating gut microbiota. This study aimed to elucidate whether the association between P. hominis infections and the increased incidence of colon cancer is related to changes in gut microbiota. Therefore, the gut microbiota patients with colon cancer who were infected with P. hominis and uninfected patients with colon cancer were analyzed by 16S rRNA high-throughput sequencing. The results demonstrated that patients with colon cancer who were not infected with P. hominis showed increased gut bacterial diversity, a higher relative abundance of Alcaligenes sp., Leucobacter sp., Paraprevotella sp., Ruminococcaceae UCG-002, and a significant reduction in the abundance of Veillonella sp., compared to individuals without colon cancer. Additionally, the relative abundance of the Ruminococcaceae UCG-002 and the Eubacterium eligens groups was reduced, while the relative abundance of bacteria associated with colon cancer, including Flavonifractor sp., Lachnoclostridium sp., and the Ruminococcus gnavus group, increased significantly in patients with colon cancer who were infected with P. hominis, compared to those of uninfected patients with colon cancer. In conclusion, these results suggested that P. hominis infections may aggravate the development of colon cancer and the findings provide new insights for subsequent in-depth studies on the pathogenesis, diagnosis, and prevention of colon cancer.

show abstract

“…Radiation therapy could induce infertility problems in patients. Moreover, non-specific delivery of chemodrugs to off-target sites can ultimately cause unwanted side effects such as gastrointestinal toxicity, liver toxicity, and hematologic disorders [ 5 , 6 ]. Notably, tumor recurrence occurs in 30–50% of CC patients after chemotherapy [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Colon Cancer Recurrence via Exogenous TRAIL Delivery Using Gel-like Coacervate Microdroplets

Kim

Jwa

Hong

et al. 2022

Gels

View full text Add to dashboard Cite

Colon cancer (CC) belongs to the three major malignancies with a high recurrence rate. Therefore, a novel drug delivery system that can prevent CC recurrence while minimizing side effects is needed. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) has recently been spotlighted as a protein drug that can induce apoptosis of cancer cells specifically. However, its short in vivo half-life is still a challenge to overcome. Hence, in this study, a gel-like mPEGylated coacervate (mPEG-Coa) delivery platform was developed through electrostatic interaction of mPEG-poly(ethylene arginylaspartate diglyceride) (mPEG-PEAD) and heparin for effective protection of cargo TRAIL, subsequently preserving its bioactivity. mPEG-Coa could protect cargo TRAIL against protease. Sustained release was observed for a long-term (14 days). In addition, recurrence of HCT-116 cells was suppressed when cells were treated with TRAIL-loaded mPEG-Coa for 7 days through long-term continuous supply of active TRAIL, whereas re-proliferation occurred in the bolus TRAIL-treated group. Taken together, these results suggest that our gel-like mPEG-Coa could be utilized as a functional delivery platform to suppress CC recurrence by exogenously supplying TRAIL for a long time with a single administration.

show abstract

Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment

Cited by 48 publications

References 225 publications

Inspirations of Cobalt Oxide Nanoparticle Based Anticancer Therapeutics

Inspirations of Cobalt Oxide Nanoparticle Based Anticancer Therapeutics

Changes of gut microbiota in colorectal cancer patients with Pentatrichomonas hominis infection

Inhibition of Colon Cancer Recurrence via Exogenous TRAIL Delivery Using Gel-like Coacervate Microdroplets

Contact Info

Product

Resources

About